Abcam, ab259246, Human ZDHHC7 knockout HeLa cell lysate

Size: 1Kit
ZDHHC7 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 131 bp insertion in exon3 and 1 bp insertion in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 131 bp insertion in exon3 and 1 bp insertion in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ZDHHC7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ZDHHC7 also known as Zinc Finger DHHC-Type Palmitoyltransferase 7 is an enzyme with a molecular mass of approximately 66 kDa. This protein plays an important role in the palmitoylation process which involves attaching palmitic acid to cysteine residues of target proteins. ZDHHC7 is widely expressed in various tissues including neurons liver and heart highlighting its importance in different physiological processes. This protein acts by facilitating the transfer of palmitate to substrates which can influence their localization and stability within cells.
Biological function summary
Zinc Finger DHHC-Type Palmitoyltransferase 7 influences cell signaling and membrane trafficking. It is part of a multi-protein complex that ensures the accurate delivery of proteins to cellular membranes where they perform specific functions. ZDHHC7 modifies signaling molecules impacting pathways related to growth and development. The lipid modification of proteins by ZDHHC7 can also affect cellular communication contributing to the regulation of signal transduction and vesicular transport across different cell types.
Pathways
ZDHHC7 participates in the palmitoylation pathway which is essential for the membrane association and function of many signaling proteins. The Hedgehog signaling pathway is one significant pathway where ZDHHC7 exerts its influence modulating the activity of proteins like Shh. ZDHHC7-related palmitoylation affects the Ras family of GTPases which are vital players in cell proliferation and differentiation. This activity fosters dynamic changes in the cell membrane composition aligning with various cellular reactiveness in response to environmental cues.
Abnormalities in ZDHHC7 function have been linked to Huntington's disease and cancer. Disruptions in its palmitoylation activity can lead to the mislocalization and dysfunction of proteins that are critical for neural stability and cell cycle regulation. In Huntington's disease ZDHHC7 interacts with mutant huntingtin protein which alters its normal palmitoylation pattern. In cancer abnormal ZDHHC7 expression affects proteins like oncogenic Ras enhancing oncogenesis. Understanding these interactions offers avenues for potential therapeutic strategies targeting the aberrant activity of these proteins in diseases.